title: Association between uterine leiomyomas and the biochemical screening test results in the first and second trimester of pregnancy: a pilot study.
abstract: OBJECTIVE
  The presence of the uterine leiomyomas may change the concentrations of the screening serum markers and so after the risk calculation of the fetal chromosomal abnormalities.
  
  
  OBJECTIVE
  To estimate the influence of the uterine leiomyomas on the first and second trimester serum markers concentrations.
  
  
  METHODS
  The studied group consisted of 127 women between 11 and 20 weeks of normal singleton pregnancy. In each patient, the uterine leiomyomas were diagnosed - over 20 mm in the diameter and located in the uterine wall. Seventy-seven patients had undergone the first trimester screening, 50 patients the second trimester screening. The control group consisted of 1020 women between 11 and 20 weeks of normal singleton pregnancy without uterine leiomyomas.
  
  
  RESULTS
  In the first trimester group, the pregnancy-associated plasma protein A serum concentrations were not different from the controls. The median concentrations of free beta-human chorionic gonadotrophin (β-hCG) were significantly higher (1.43 MoM). In the second trimester group, no significant differences in AFP and estriol median concentrations were observed, while the median value for free β-hCG was significantly higher (2.01 MoM) than in control group.
  
  
  CONCLUSIONS
  The presence of the uterine leiomyomas may increase maternal serum concentration of the β-hCG and so after the rate of the false positive results of the prenatal screening tests.
authors.affiliation: Fetal Medicine and Gynecology Department, Medical University of Łódź, Poland.
authors.forename: Piotr
authors.initials: P
authors.lastname: Sieroszewski
authors.forename: Dorota
authors.initials: D
authors.lastname: Wierzbicka
authors.forename: Lukasz
authors.initials: L
authors.lastname: Bober
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Perenc
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D018997:Chorionic Gonadotropin, beta Subunit, Human / Q000097:blood*; D004964:Estriol / Q000097:blood; D005189:False Positive Reactions; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000097:blood*; D008403:Mass Screening; D010865:Pilot Projects; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000097:blood*; D011261:Pregnancy Trimester, First; D011262:Pregnancy Trimester, Second; D011266:Pregnancy-Associated Plasma Protein-A / Q000378:metabolism; D011296:Prenatal Diagnosis; D014594:Uterine Neoplasms / Q000097:blood*; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D015415:Biomarkers; D018997:Chorionic Gonadotropin, beta Subunit, Human; D000509:alpha-Fetoproteins; D011266:Pregnancy-Associated Plasma Protein-A; D004964:Estriol